Study Details
A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone
Clinicaltrials.gov ID
Astellas Study ID
9785-MA-1001
EudraCT ID
2013-004711-50
Condition
Prostate Cancer
Phase
Phase 3
Age
18 Years - N/A
Sex
Male
Product
enzalutamide
Type
Interventional
Trial Dates
Dec 2014 - Oct 2023
Masking
Triple (Participant, Investigator, Outcomes Assessor)
Enrollment number
688
A Randomized, Double Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated with Docetaxel Plus Prednisolone Who Have Progressed on Enzalutamide Alone
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site NO47004
Stavanger, Norway, 4011
Site SE46004
Uppsala, Sweden, 751 85
Site BE32005
Turnhout, Belgium, 2300
Site ES34007
Malaga, Spain, 29010
Site RU70003
Moscow, Russian Federation, 125284
Site RU70001
Moscow, Russian Federation, 115478
Site GB44002
Nottingham, United Kingdom, NG5 1PB
Site GB44004
Cambridge, United Kingdom, CB2 0QQ
Site TR90003
Istanbul, Turkey, 34722
Site ES34006
Valencia, Spain, 46009
Site DE49004
Wuppertal, Germany, 42103
Site GR30004
Heraklion, Greece, 71403
Site DE49002
Munster, Germany, 48149
Site FR33012
Albi, France, 81000
Site PL48002
Lodz, Poland, 93-513
Site ES34003
Madrid, Spain, 28007
Site FR33005
Suresnes, France, 92151
Site RU70002
Moscow, Russian Federation, 105077
Site PL48005
Warszawa, Poland, 04-141
Site BE32008
Wilrijk, Belgium, 2610
Site DE49017
Ulm, Germany, 89075
Site GB44018
Cardiff, United Kingdom, CF4 7XL
Site ES34008
Santander, Spain, 39008
Site ES34001
Madrid, Spain, 28040
Site FR33004
Plerin, France, 22190
Site DE49008
Aachen, Germany, 52074
Site DE49001
Hannover, Germany, 30625
Site PL48004
Gdańsk, Poland, 80-952
Site GB44014
Exeter, United Kingdom
Site AT43001
Vienna, Austria, 1090
Site ES34010
Madrid, Spain
Site PL48006
Warszawa, Poland, 02-507
Site IT39008
Naples, Italy, 80131
Site IT39010
Pavia, Italy, 27100
Site NO47005
Drammen, Norway, 3004
Site GB44020
Northwood, United Kingdom, HA62RN
Site RU70004
Obninsk, Russian Federation, 24903
Site SE46005
Kalmar, Sweden, 39185
Site FR33011
Reims, France, 51056
Site GB44007
Wirral, United Kingdom, CH63 4JY
Site GR30006
Athens, Greece, 155 62
Site PL48003
Krakow, Poland, 31-501
Site FR33002
Nîmes, France, 30907 cedex 2
Site TR90001
Ankara, Turkey, 06500
Site DE49015
Tübingen, Germany, 72076
Site GB44003
London, United Kingdom, SE1 9RT
Site NL31010
Nieuwegein, Netherlands, 3435 CM
Site IT39002
Terni, Italy, 05100
Site FR33008
Paris, France, 75014
Site DE49018
Nürtingen, Germany, 72622
Site ES34005
Lugo, Spain, 27003
Site IT39003
Milano, Italy, 20100
Site CH41005
Locarno, Switzerland, 6600
Site IT39004
Rome, Italy, 161
Site RU70005
St. Petersburg, Russian Federation, 197022
Site NO47001
Kristiansand, Norway, 4615
Site CZ42004
Brno, Czech Republic, 656 91
Site IT39001
Arezzo, Italy, 52100
Site FR33006
Vandoeuvre les Nancy, France, 54511
Site NL31002
Amsterdam, Netherlands, 1066 CX
Site GB44015
Norwich, United Kingdom, NR4 7UY
Site TR90002
Izmir, Turkey, 35340
Site CH41009
Zurich, Switzerland, CH-8038
Site CZ42003
Olomouc, Czech Republic, 77520
Site NL31003
Rotterdam, Netherlands, 3045 PM
Site GR30001
Heraklion, Greece, 70013
Site IT39013
Rome, Italy, 00152
Site ES34009
Murcia, Spain, 30008
Site GB44010
Aberdeen, United Kingdom, AB25 2ZN
Site BE32004
Ottignies, Belgium, 1340
Site CZ42001
Praha 2, Czech Republic, 12808
Site GB44017
Swansea, United Kingdom, SA2 8QA
Site ES34002
Madrid, Spain, 28041
Site FR33013
Quimper, France, 29000
Site DE49006
Heidelberg, Germany, 69120
Site BE32002
Liege, Belgium, 4000
Site FR33003
Montpellier, France, 34298 cedex 5
Site DE49010
Bergisch Gladbach, Germany, 51465
Site SE46003
Solna, Sweden, 171 76
Site SE46002
Göteborg, Sweden, 413 45
Site ES34004
Sevilla, Spain, 41013
Site RU70006
St. Petersburg, Russian Federation, 197758
Site BE32003
Bonheiden, Belgium, 2820
Site CZ42002
Plzeň -Lochotín, Czech Republic, 30460
Site DE49003
Mannheim, Germany, 68167
Site FR33014
Paris, France, 75014
Site NL31007
Blaricum, Netherlands, 1261 AN
Site IT39012
Brescia, Italy, 25126
Site AT43004
Linz, Austria, 4010
Site GR30003
Athens, Greece, 14564
Site NL31004
Hoofddorp, Netherlands, 2134 TM
Site GR30005
Thessaloniki, Greece, 54007
Site IT39005
Roma, Italy, 00128
Site GR30002
Larissa, Greece, 41110
The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website
© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.
POWERED BY:
